- Received ‘A, A’ ratings in technology assessment in June… Qualifies for special technology listing
- 6,414,000 shares offered, 64,142,610 total listed… Mirae Asset Securities as underwriter
- Founder and largest shareholder Nam Do-hyun, a Samsung Medical Center professor, holds a 38.4% stake
[by Ji, Yong Jun] Aimed Bio, a company specializing in antibody-drug conjugate (ADC) and a recipient of investment from Samsung, has initiated procedures for listing on the KOSDAQ under the technology special listing program.
According to industry sources on July 25, Aimed 바카라 토토 사이트 submitted its preliminary listing application to the Korea Exchange on July 24. The company intends to list a total of 64,142,611 shares, which includes 6,414,100 shares allocated for public offering. Mirae Asset Securities will serve as the lead manager for the listing process.
Aimed 바카라 토토 사이트 qualified for the technology special listing program by obtaining ‘A’ and ‘A’ ratings from two technology evaluation agencies designated by the Korea Exchange in June. Founded by Professor Nam Do-hyun of Samsung Medical Center, the company is dedicated to developing innovative novel drugs, with a primary focus on ADCs and brain disease treatments. Nam, the largest shareholder, holds a 38.4% stake in the company.
Aimed 바카라 토토 사이트 gained significant attention after securing investment from the ‘Samsung Life Science Fund.’ Despite challenging market conditions, the company successfully raised KRW 40 billion (approximately USD 29.1 million) through a Series B funding round in 2024. Furthermore, Aimed 바카라 토토 사이트 completed its pre-IPO (pre-listing investment attraction) round ahead of schedule, attracting a total of KRW 51.1 billion from major Korean institutional investors.
Aimed 바카라 토토 사이트 has established a differentiated ADC pipeline by leveraging novel target discovery, proprietary antibody development, intermediary research technologies, and its in-house linker-payload platform tailored to address unmet medical needs. Building on these integrated R&D capabilities, the company successfully entered into a technology transfer agreement with the U.S.-based 바카라 토토 사이트haven for ‘AMB302 (development code)’ last year. More recently, it further demonstrated its technological competitiveness by signing a co-development and licensing agreement with SK Plasma for ‘AMB303.’
“Through this listing, we aim to reinforce our growth momentum and leap forward to become a global 바카라 토토 사이트technology company at the forefront of developing innovative anticancer therapies,” said Her Nam-gu, CEO of Aimed 바카라 토토 사이트.